Brain Peptide

• BPC-157 is a penta-decapeptide composed of 15 amino acids. It is a partial sequence of the body protection compound (BPC) that was discovered in and isolated from human gastric juice. Animal studies have shown it to accelerate the healing of many different wounds, including muscle, tendon, and damaged ligaments. Those who suffer from discomfort due to muscle sprains, tears and damage may benefit from treatment with this peptideAdditionally, BPC-157 has shown to protect organs and aids in the prevention of gastric ulcers. BPC-157 acts systemically in the digestive tract to combat leaky gut, IBS, gastro-intestinal cramps, and Crohn’s disease. This peptide has also been known to exhibit analgesic characteristics. Research has shown its ability to help skin burns heal at a faster rate by increasing blood flow to damaged tissues. This is because BPC-157 significantly accelerates reticulin and collagen formation as well as angiogenesis.
• TB-500 is a synthetic derivative of Thymosin, a hormone secreted from the thymus. Its primary function is to stimulate the production of T cells, which are an important part of the immune system. Thymosin also assists in the development of B cells to plasma cells, a process that produces antibodies. TB-500 has been found to play an important role in the protection, regeneration, and remodeling of injured or damaged tissues. Thymosin Beta 4, the predominant form of Thymosin, is currently being trialed as a potential therapy for HIV, AIDS, and Influenza. Currently, Thymosin Beta 4 is most often prescribed for acute injury, surgical repair and for senior athletes.
• Thymosin Alpha 1 (Ta1) is a peptide naturally occurring in the thymus that has long been recognized for modifying, enhancing, and restoring immune function. Ta1 helps the body induce host-derived immune effectors that improve ​various immunomodulatory properties. This leads to augmentation of T lymphocyte function including modulation of interleukin-2 (IL-2), stimulation of interferon-g (IFN-g) production,​ ​induction of T lymphocyte and natural killer (NK) cells, and stimulation of thymopoiesis, the process that turns thymocytes into mature T-cells. Ta1 has also been reported to up-regulate MHC Class I expression.Thymosin Alpha 1 has been utilized in the treatment of immunocompromised states and malignancies, as an enhancer of vaccine response, and as a means of curbing morbidity and mortality in sepsis and numerous infections. Studies have postulated that Thymosin Alpha 1 could help improve the outcome in severely ill respiratory virus patients by repairing damage caused by overactivation of lymphocytic immunity.

Protocol Instructions

Inject 1 syringe Monday-Friday subcutaneously into the abdomen or buttocks in the evening. Injection frequency is 5 days on and 2 days off.

*Must stay refrigerated.